Stifel maintains IGM Biosciences stock hold with $2.50 target

On Friday, Stifel analysts reiterated a Hold rating for IGM Biosciences stock (NASDAQ:IGMS), maintaining the $2.50 price target against the current price of $1.32. The reiteration follows the company’s release of its annual 10-K filing, leading Stifel analysts to update their financial model for IGM Biosciences. According to InvestingPro data, the stock has experienced a significant decline, falling 88.46% over the past year, though it maintains strong liquidity with more cash than debt on its balance sheet. Despite significant organizational changes at IGM Biosciences, including the discontinuation of its wholly-owned pipeline and a workforce reduction exceeding 70%, Stifel’s investment thesis remains unchanged. InvestingPro analysis reveals the company’s challenging position, with a weak Financial Health Score of 1.47 out of 5, though it maintains a healthy current ratio of 5.22, indicating strong short-term liquidity.

The company’s strategic shift also involves evaluating a range of internal and external strategic alternatives. Stifel’s $2.50 target price factors in an estimated year-end 2025 net cash position of approximately $2 per share on a fully-diluted basis. Additionally, the price target includes a substantially discounted valuation of around $0.50 per share, fully-diluted, for the ongoing collaboration with Sanofi (NASDAQ:SNY) which focuses on IgM-based agonists targeting autoimmune and inflammatory diseases. This partnership has three preclinical candidates with the potential to achieve over $3 billion in milestone payments.

Stifel’s assessment of IGM Biosciences’ financial prospects takes into account the impact of these strategic decisions on the company’s valuation. Despite the setbacks and restructuring, the collaboration with Sanofi remains in place, providing some potential for future value creation through its preclinical candidates.

The analyst’s commentary sheds light on the rationale behind the maintained Hold rating, indicating a cautious approach to the stock. The analysis suggests that while the company has faced challenges and has significantly scaled back its operations, there is still some inherent value in its partnership and cash reserves.

IGM Biosciences has not made any public statements regarding Stifel’s rating and price target reiteration. Investors watching the stock’s performance should note that InvestingPro indicates the next earnings report is scheduled for March 27, 2025, which could provide crucial updates on the company’s strategic initiatives. The company’s stock performance will continue to be observed by investors as it navigates through its strategic realignment and ongoing collaboration efforts in the biotechnology sector.

In other recent news, IGM Biosciences announced the discontinuation of two key drug candidates, imvotamab and IGM-2644, aimed at treating autoimmune diseases. This decision has led to significant changes in the company’s operations, including a workforce reduction of 73% and a shift in focus to its collaboration with Sanofi. The halted developments have prompted several financial firms to adjust their outlook on IGM Biosciences. Truist Securities and Morgan Stanley (NYSE:MS) both slashed their price targets for the company to $2.00, citing the discontinuation as a major factor. Stifel downgraded the stock from Buy to Hold, reducing its price target to $2.50, while RBC Capital Markets lowered its rating to Sector Perform with a new price target of $1.50. Analysts from these firms pointed to the strategic challenges and uncertainties facing IGM Biosciences as reasons for their revised assessments. The company is now exploring strategic alternatives as it navigates this period of transition. Investors will be watching closely to see how IGM Biosciences leverages its partnership with Sanofi to rebuild its project pipeline.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.